Immunogen Inc., of Waltham, Mass., said it intends to offer and sell, subject to market and other conditions, 12 million shares of its common stock in an underwritten public offering and will grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered.